A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent
Tianshu Xiao(Nanyang Technological University), Bing Chen(Xinjiang Academy of Agricultural and Reclamation Science), Jun Zhang(Harvard University), Brian D. Quinlan(Scripps Research Institute), Hanqin Peng(Boston Children's Hospital), Christy L. Lavine(Beth Israel Deaconess Medical Center), Jianming Lü(Guangzhou First People's Hospital), Sophia Rits‐Volloch(Boston Children's Hospital), Lindsay G. A. McKay(Boston University), Michael Farzan(Broad Institute), Rebecca I. Johnson(Boston University), Anthony Griffiths(Boston University), Michael S. Seaman(Beth Israel Deaconess Medical Center), Yongfei Cai(Boston Children's Hospital), Shen Lu(Codex Biosolutions (United States)), Nadia Storm(Albert Einstein College of Medicine)
Cited by 152
Related Papers
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
|Science|2010|1.8k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Distinct conformational states of SARS-CoV-2 spike protein
|Science|2020|1.4k
The broad-spectrum antiviral functions of IFIT and IFITM proteins
|Nature reviews. Immunology|2012|855